Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AC Immune (ACIU) Payables (2016 - 2025)

AC Immune (ACIU) has disclosed Payables for 9 consecutive years, with $3.0 million as the latest value for Q4 2024.

  • On a quarterly basis, Payables rose 60.3% to $3.0 million in Q4 2024 year-over-year; TTM through Dec 2024 was $3.0 million, a 60.3% increase, with the full-year FY2024 number at $3.0 million, up 62.3% from a year prior.
  • Payables was $3.0 million for Q4 2024 at AC Immune, up from $1.9 million in the prior quarter.
  • In the past five years, Payables ranged from a high of $3.0 million in Q4 2024 to a low of $964322.4 in Q4 2022.
  • A 5-year average of $2.1 million and a median of $2.2 million in 2021 define the central range for Payables.
  • Peak YoY movement for Payables: surged 1583.81% in 2020, then crashed 55.61% in 2022.
  • AC Immune's Payables stood at $2.4 million in 2020, then fell by 10.08% to $2.2 million in 2021, then plummeted by 55.61% to $964322.4 in 2022, then skyrocketed by 96.29% to $1.9 million in 2023, then surged by 60.3% to $3.0 million in 2024.
  • Per Business Quant, the three most recent readings for ACIU's Payables are $3.0 million (Q4 2024), $1.9 million (Q4 2023), and $964322.4 (Q4 2022).